β-Lactam Antibiotics Renaissance

Since the 1940s β-lactam antibiotics have been used to treat bacterial infections. However, emergence and dissemination of β-lactam resistance has reached the point where many marketed β-lactams no longer are clinically effective. The increasing prevalence of multidrug-resistant bacteria and the pro...

Full description

Bibliographic Details
Main Authors: Wenling Qin, Mauro Panunzio, Stefano Biondi
Format: Article
Language:English
Published: MDPI AG 2014-05-01
Series:Antibiotics
Subjects:
Online Access:http://www.mdpi.com/2079-6382/3/2/193
id doaj-f3b075e6df7e4069a581218298aa5875
record_format Article
spelling doaj-f3b075e6df7e4069a581218298aa58752020-11-25T00:12:07ZengMDPI AGAntibiotics2079-63822014-05-013219321510.3390/antibiotics3020193antibiotics3020193β-Lactam Antibiotics RenaissanceWenling Qin0Mauro Panunzio1Stefano Biondi2ISOF-CNR Department of Chemistry "G. Ciamician", Via Selmi, 2 I-40126 Bologna, ItalyISOF-CNR Department of Chemistry "G. Ciamician", Via Selmi, 2 I-40126 Bologna, ItalyAllecra Therapeutics SAS, 13, rue de Village-Neuf, F-68300 St-Louis, FranceSince the 1940s β-lactam antibiotics have been used to treat bacterial infections. However, emergence and dissemination of β-lactam resistance has reached the point where many marketed β-lactams no longer are clinically effective. The increasing prevalence of multidrug-resistant bacteria and the progressive withdrawal of pharmaceutical companies from antibiotic research have evoked a strong reaction from health authorities, who have implemented initiatives to encourage the discovery of new antibacterials. Despite this gloomy scenario, several novel β-lactam antibiotics and β-lactamase inhibitors have recently progressed into clinical trials, and many more such compounds are being investigated. Here we seek to provide highlights of recent developments relating to the discovery of novel β-lactam antibiotics and β-lactamase inhibitors.http://www.mdpi.com/2079-6382/3/2/193β-lactam antibioticsβ-lactamase inhibitorsbacterial infections
collection DOAJ
language English
format Article
sources DOAJ
author Wenling Qin
Mauro Panunzio
Stefano Biondi
spellingShingle Wenling Qin
Mauro Panunzio
Stefano Biondi
β-Lactam Antibiotics Renaissance
Antibiotics
β-lactam antibiotics
β-lactamase inhibitors
bacterial infections
author_facet Wenling Qin
Mauro Panunzio
Stefano Biondi
author_sort Wenling Qin
title β-Lactam Antibiotics Renaissance
title_short β-Lactam Antibiotics Renaissance
title_full β-Lactam Antibiotics Renaissance
title_fullStr β-Lactam Antibiotics Renaissance
title_full_unstemmed β-Lactam Antibiotics Renaissance
title_sort β-lactam antibiotics renaissance
publisher MDPI AG
series Antibiotics
issn 2079-6382
publishDate 2014-05-01
description Since the 1940s β-lactam antibiotics have been used to treat bacterial infections. However, emergence and dissemination of β-lactam resistance has reached the point where many marketed β-lactams no longer are clinically effective. The increasing prevalence of multidrug-resistant bacteria and the progressive withdrawal of pharmaceutical companies from antibiotic research have evoked a strong reaction from health authorities, who have implemented initiatives to encourage the discovery of new antibacterials. Despite this gloomy scenario, several novel β-lactam antibiotics and β-lactamase inhibitors have recently progressed into clinical trials, and many more such compounds are being investigated. Here we seek to provide highlights of recent developments relating to the discovery of novel β-lactam antibiotics and β-lactamase inhibitors.
topic β-lactam antibiotics
β-lactamase inhibitors
bacterial infections
url http://www.mdpi.com/2079-6382/3/2/193
work_keys_str_mv AT wenlingqin blactamantibioticsrenaissance
AT mauropanunzio blactamantibioticsrenaissance
AT stefanobiondi blactamantibioticsrenaissance
_version_ 1725401181586456576